## Kezar Life Sciences Shutters After Four-Month FDA Delay Derails Critical Liver Disease Trial
A four-month regulatory delay from the U.S. Food and Drug Administration (FDA) forced a small biotech company to close its doors, illustrating the precarious path for firms navigating the drug approval process. Kezar Life Sciences had reached a breakthrough agreement with the FDA in February on a clinical trial plan for its treatment for autoimmune hepatitis, a rare and debilitating liver disease. The fatal flaw was timing: that critical agreement came four months after the agency abruptly canceled a scheduled meeting to discuss the trial design in October, leaving the company in limbo without explanation.

Without clarity from regulators, Kezar's forward path became unclear. Investor confidence evaporated, and the company was forced to initiate a wind-down. It laid off most of its approximately 60 employees, auctioned off lab equipment, and sold office furniture. In a stark symbol of dwindling hope, the company kept only one conference room's table and chairs, reserved for a potential last-minute meeting with the FDA.

The case spotlights the immense pressure and existential risk small biotech firms face from regulatory uncertainty. A single delayed meeting can derail years of research, sever investor lifelines, and shutter a company before its science can be fully evaluated. This incident raises questions about communication and process within the FDA's review system, particularly for treatments targeting rare diseases with few options.
---
- **Source**: STAT News
- **Sector**: The Lab
- **Tags**: FDA, biotech, clinical trials, regulatory delay, autoimmune hepatitis
- **Credibility**: unverified
- **Published**: 2026-04-06 08:56:53
- **ID**: 51198
- **URL**: https://whisperx.ai/en/intel/51198